

Watch for Growth Slowdown With Stimulants

BY JEFF EVANS
Senior Writer

NEW YORK — Significant growth slowdown during treatment with stimulants may occur in a small subset of children who require closer monitoring and referral, Dr. Harold E. Carlson said at a psychopharmacology update sponsored by the American Academy of Child and Adolescent Psychiatry.

Height velocity, or yearly growth, typi-

cally slows for the first few years of stimulant therapy and then resumes at a nearly normal rate, said Dr. Carlson, head of endocrinology at the State University of New York at Stony Brook.

Final adult height is usually normal with long-term use of stimulants. However, a small subset of patients, perhaps 10%, have a more significant slowdown of growth, Dr. Carlson said.

"I don't think anybody has a good handle on how many [children experience

this significant slowdown], and we certainly don't have a good idea as to how to identify them ahead of time," he said.

Because the secretion of growth hormone in these children is normal, researchers have speculated that the slowdown may be related to a decrease in food intake while on stimulants. "That's probably it," Dr. Carlson suggested, because "people on stimulants, especially on higher doses, often lose their appetite."

The slowdown of growth is greater in

prepubertal children, boys, children who are taller or overweight, and children who use sustained-release formulations.

Dr. Carlson advised obtaining prior growth records and measuring the height and weight of children before beginning stimulants. Height and weight should be measured and plotted every 6 months while on treatment. A decrease of more than one standard deviation in height for age while on treatment should prompt consultation to exclude other disorders. ■

Continued from previous page

nephine reuptake inhibitor. Those cases, which are now under review, involve arrhythmias, syncope, cardiac arrest, MI, and stroke in pediatric and adult patients, Dr. Gelperin said.

Reports of sudden deaths in 12 children and 8 adults on the amphetamine products Adderall and Adderall XR resulted in a label change in August 2004 and a warning about its use in adults and children with structural heart anomalies. Those drugs were taken off the market temporarily in Canada.

Short-term studies that measure the effects of these drugs on blood pressure and pulse are among the panel recommendations for studying this potential risk in children and adults. Another suggestion was a study that would evaluate left ventricular wall/myocardial thickness in people who have been on these drugs for a period of time with echocardiograms, comparing them with similar people who have not been on the drugs.

Dr. John Moore, director of the diagnostic and interventional catheterization program in the division of pediatric cardiology at Mattel Children's Hospital at the University of California, Los Angeles, suggested a study in children with cardiovascular risk factors. About 40%-50% of children with congenital heart disease have ADHD, but only about 10% of them are treated because practitioners are nervous about prescribing these drugs.

At the press conference held after the meeting, Dr. Robert Temple, director of the FDA's Office of Drug Evaluation—which includes psychiatric drugs—said that the agency would review the panel's comments and that the same issues would be brought before the pediatric advisory panel this month. He added that any conclusion about how to label the drugs has to take into account that overstating potential risks can be harmful and can frighten people. He added that ADHD is a serious condition, a point acknowledged by panel members.

He described the information available as a complicated "mélange" of data on sudden death, which has a degree of uncertainty; the properties of the drugs, which can raise blood pressure and heart rate and can result in adverse effects in patients with heart failure; fairly good certainty about the pharmacologic effects of the drugs; and uncertainty about what the consequences of the pharmacologic effects might mean.

"We're going to have to sort all that out," Dr. Temple said. ■



ARICEPT helps patients be more like themselves longer™

- Helped keep patients in the community for more than 5 years^{1*†}
- Is proven effective in cognition, function, and behavior²⁻⁵
- Caregivers spend less time assisting patients with everyday activities⁶
- Established safety and tolerability

* Results from an observational follow-up of nursing home placement in mild to moderate AD patients (MMSE 10-26) previously enrolled in 1 of 3 randomized, double-blind, placebo-controlled trials with open-label extension phases.

† As with all studies of this type, results may be attributable to various factors. ARICEPT treatment was one such factor.

ARICEPT is indicated for mild to moderate dementia of the Alzheimer's type.

The most common adverse events in clinical trials with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. In clinical trials, syncopal episodes have been reported (2% for ARICEPT versus 1% for placebo). Cholinesterase inhibitors have the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.

Clinical studies of ARICEPT have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Please see brief summary of prescribing information on adjacent page.

ARICEPT
(donepezil HCl)

ONCE-A-DAY
ODT
Orally Disintegrating
Tablets (5MG and 10MG)

ONCE-A-DAY
ARICEPT
(donepezil HCl)
5-MG AND 10-MG TABLETS

References: 1. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. *J Am Geriatr Soc.* 2003;51:937-944.
2. Winblad B, Engedal K, Soininen H, et al, and the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology.* 2001;57:489-495.
3. Mohs RC, Doody RS, Morris JC, et al, for the "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology.* 2001;57:481-488. 4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch Intern Med.* 1998;158:1021-1031.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology.* 1998;50:136-145.
6. Feldman H, Gauthier S, Hecker J, et al, and The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. *J Am Geriatr Soc.* 2003;51:737-744. AR262998C